Get started

ABBV

ABBV, is it a buy right now?☝️ Losing patent protection for a top-selling blockbuster drug is a big setback for any pharmaceutical company, but this can also give us great opportunities. They have done a great strategic-movement by acquiring Allergan. It's down 18% from last July 17 high, earnings are close. I believe, yes, it's a good moment to START doing COST-AVERAGE. The price is almost getting closer to the 50% Fibonacci (from last Mar 20). I'm protecting an optimistic retracement to 127% (at $108.58) Fibonacci (drawing from today), very close to the analyst's current average price target at $109.21. A more conservative take profit would be at $95. - P/E GAAP (TTM) of 18.63, sector media of 35.57 👍 - Forward P/E of 6.94 👍 - PEG GAAP (TTM) of 0.29, sector media of 0.88 👍 - EV / EBITDA (TTM) of 13.76 in a sector media of 19.29 👍 - Debt / Eq of 5.4 😐 - Dividend yield of 5.60% 😍 Nothing else to say, it's a great company, with great dividends. I'm in! 👌 This isn't trading advice. I've no idea what I'm talking about 😉. Trade with caution! 🚨 Have a good day! 🤟
NYSE:ABBVLong
by UnknownUnicorn12013771
1
$ABBV AbbVie Inc. - Double Bottom, Bullish Options Activity$ABBV AbbVie Inc. - Looking like a possible double bottom just under $86 after about a two month bear move. Expecting a strong move in the near term once this can clear the 200d ema (currently ~$89.00). Note: earnings upcoming, expected 10/30/20. Huge Bullish Options Flow in this name today: $122M in January'21 calls traded today (varying strikes, most deep ITM), on avg 8x OI - 58k contracts in total. Definitely looks like a large hedge fund trade. Positive fundamental news out today (possible driver of bullish options activity): "The National Institutes of Health said is running a mid-stage clinical trial evaluating a monoclonal antibody it developed with the privately held Boehringer Ingelheim in combination with remdesivir as a COVID-19 treatment." Source: MarketWatch.com -> www.marketwatch.com Medium term target: $107 by year-end Note: This is NOT investment advice.
NYSE:ABBVLong
by Triple_Barrel_Capital
3
ABBV an Entry Point into the Wild World of BiotechBiotechnology and pharmaceutical companies have been quickly cycling through overbought and oversold. The problem has been so problematic that Sorrento Therapeutics had to specifically claim they were not a “pump and dump” scheme. Any whisper of a "cure" for Covid-19 has investors rushing to the entrance and quickly fleeing after results are what they had expected (an image of people rushing toward the exit and getting stuck in door comes to my mind). People who know the biotech sector have been cautiously watching the spectacle and trying to avoid getting trampled in a stampede. To be clear: your average investor is getting burned in the vaccine-hunt game. AbbVie "ABBV" is (and has been) a reliable pharmaceutical and biotechnology company for some time. The company is known for its generous dividend – previously at a yield of 5.20%. The company has a robust balance sheet with a Quick Ratio of 3.03 and a Current Ratio of 3.14. In the world of biotech, research and development is everything. ABBV pipeline is stacked with potential drug candidates many of which are in Phase 3 of development according to AbbVie’s investor relations brochure. From a technical analysis standpoint, the moving averages appear to be moving toward a positive crossover – EMA10 = 91.00, EMA20 = 90.88 EMA25 = 90.87. The stock does not look overbought or oversold according to the Stoch RSI and Money Flow Indicator. However, the MACD indicator shows that there may be a further swing downward before moving into positive territory. Finally, the linear regression model is one of the few biotechnology companies that is not inverse or appears caught in a sideway pattern. LONG ABBV purchased today (06-02-2020) @ 90.86.
NYSE:ABBVLong
by luminaryfi
6